Usefulness of Random-start Progestin-primed Ovarian Stimulation for Fertility Preservation

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2022 Jan 5

PMID 34983605

Citations 3

Authors

Haipeng Huang

Yukiko Itaya

Kouki Samejima

Shunichiro Ichinose

Tatsuya Narita

Shigetaka Matsunaga

Masahiro Saitoh

Yasushi Takai

Affiliations

Soon will be listed here.

Abstract

Background: Progestin-primed ovarian stimulation (PPOS) has been used in infertility cases in recent years, and several reports have stated that it has oocyte collection results similar to those of gonadotropin-releasing hormone antagonist (GnRH-ant) protocol. For emergency fertility preservation, random-start ovarian stimulation is usually recommended. Therefore we compared the clinical outcomes of random-start PPOS with those of conventional random-start GnRH-ant protocols in fertility-preserving cases.

Methods: We retrospectively examined 86 cycles of oocyte collection, of which 56 were random-start GnRH-ant and 30 were random-start PPOS for fertility preservation at our hospital between January 2016 and April 2021. The primary outcome was the number of mature oocytes per cycle. The secondary outcome was the number of vitrified blastocysts per cycle for embryo freezing cases.

Results: No significant differences were noted in the number of days of stimulation, total dose of gonadotropin preparation, and the number of mature oocytes and vitrified blastocysts. The number of hospital visits for monitoring was significantly lower in the PPOS group. The start of menstruation before oocyte collection was significantly less in the PPOS group.

Conclusions: Random-start PPOS and GnRH-ant were similar in oocyte collection results. PPOS can reduce the number of hospital visits, thus reducing patient stress. PPOS at the start of the luteal phase can prevent the start of menstruation during ovarian stimulation.

Citing Articles

The construction of machine learning-based predictive models for high-quality embryo formation in poor ovarian response patients with progestin-primed ovarian stimulation.

Xiao Y, Hu Y, Lv X, Huang L, Geng L, Liao P Reprod Biol Endocrinol. 2024; 22(1):78.

PMID: 38987797 PMC: 11234746. DOI: 10.1186/s12958-024-01251-5.

Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.

Saito S, Yamada M, Yano R, Takahashi K, Ebara A, Sakanaka H J Ovarian Res. 2023; 16(1):159.

PMID: 37563616 PMC: 10416401. DOI: 10.1186/s13048-023-01250-x.

Progestin-primed ovarian stimulation for fertility preservation in women with cancer: A comparative study.

Filippi F, Reschini M, Polledri E, Cecchele A, Guarneri C, Vigano P PLoS One. 2023; 18(3):e0280238.

PMID: 36976781 PMC: 10047511. DOI: 10.1371/journal.pone.0280238.

References

Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X . Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing Fertilization Treatment: A Randomized Controlled Trial. Front Endocrinol (Lausanne). 2019; 10:796. PMC: 6882854. DOI: 10.3389/fendo.2019.00796. View

Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q . Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015; 104(1):62-70.e3. DOI: 10.1016/j.fertnstert.2015.03.022. View

Kofinas J, Mehr H, Ganguly N, Biley Y, Bochkovsky S, McCulloh D . Is it the egg or the endometrium? Elevated progesterone on day of trigger is not associated with embryo ploidy nor decreased success rates in subsequent embryo transfer cycles. J Assist Reprod Genet. 2016; 33(9):1169-74. PMC: 5010810. DOI: 10.1007/s10815-016-0752-y. View

La Marca A, Capuzzo M, Sacchi S, Imbrogno M, Spinella F, Varricchio M . Comparison of euploidy rates of blastocysts in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation. Hum Reprod. 2020; 35(6):1325-1331. DOI: 10.1093/humrep/deaa068. View

Yildiz S, Turkgeldi E, Angun B, Eraslan A, Urman B, Ata B . Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril. 2019; 112(4):677-683. DOI: 10.1016/j.fertnstert.2019.06.009. View

Baerwald A, Adams G, Pierson R . Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2011; 18(1):73-91. DOI: 10.1093/humupd/dmr039. View

Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O . New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018; 298(3):663-671. DOI: 10.1007/s00404-018-4856-8. View

Danis R, Pereira N, Elias R . Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy. Curr Pharm Biotechnol. 2017; 18(8):609-613. DOI: 10.2174/1389201018666170808122531. View

Gurbuz A, Gode F . Dydrogesterone-primed ovarian stimulation is an effective alternative to gonadotropin-releasing hormone antagonist protocol for freeze-all cycles in polycystic ovary syndrome. J Obstet Gynaecol Res. 2020; 46(8):1403-1411. DOI: 10.1111/jog.14267. View

10.

. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394(10204):1159-1168. PMC: 6891893. DOI: 10.1016/S0140-6736(19)31709-X. View

11.

Yu S, Long H, Chang H, Liu Y, Gao H, Zhu J . New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018; 33(2):229-237. DOI: 10.1093/humrep/dex367. View

12.

Kasum M, von Wolff M, Franulic D, cehic E, Klepac-Pulanic T, Oreskovic S . Fertility preservation options in breast cancer patients. Gynecol Endocrinol. 2015; 31(11):846-51. DOI: 10.3109/09513590.2015.1081684. View

13.

Gardner D, Lane M, Stevens J, Schlenker T, Schoolcraft W . Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000; 73(6):1155-8. DOI: 10.1016/s0015-0282(00)00518-5. View

14.

Cakmak H, Katz A, Cedars M, Rosen M . Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013; 100(6):1673-80. DOI: 10.1016/j.fertnstert.2013.07.1992. View

15.

Mathieu dArgent E, Ferrier C, Zacharopoulou C, Ahdad-Yata N, Boudy A, Cantalloube A . Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols. J Ovarian Res. 2020; 13(1):18. PMC: 7020543. DOI: 10.1186/s13048-020-00620-z. View